Valuation: Vaxart, Inc.

Market Cap 136M 118M 110M 101M 190M 12.98B 193M 1.3B 508M 6.5B 511M 499M 21.67B P/E 2026 *
-3.5x
P/E 2027 * -0.66x
Enterprise Value 136M 118M 110M 101M 190M 12.98B 193M 1.3B 508M 6.5B 511M 499M 21.67B EV / Sales 2026 *
1.15x
EV / Sales 2027 * 57.9x
Free-Float
98.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+5.95%
Current month+11.83%
1 month+11.41%
3 months-12.44%
6 months+6.70%
Current year+74.34%
1 week 0.53
Extreme 0.5325
0.62
1 month 0.44
Extreme 0.44
0.64
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
9.5
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 17/03/2024
Chief Tech/Sci/R&D Officer 59 29/02/2024
Director of Finance/CFO - 18/05/2025
Director TitleAgeSince
Director/Board Member 68 20/04/2021
Director/Board Member 76 03/08/2022
Director/Board Member 79 31/12/2021
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+5.95%+63.48%-13.01% 136M
+2.07%+13.76%+65.44%+106.53% 71.56B
-2.20%-3.33%+32.55%+61.41% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
+0.35%+1.75%+39.46%-19.76% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -0.57%+3.66%+54.06%+180.53% 26.66B
Weighted average by Cap. -0.52%+3.63%+50.54%+162.80%

Financials

2026 *2027 *
Net sales 119M 103M 96.37M 87.87M 165M 11.32B 168M 1.13B 443M 5.67B 445M 436M 18.9B 2.35M 2.04M 1.91M 1.74M 3.28M 224M 3.33M 22.48M 8.78M 112M 8.82M 8.63M 375M
Net income -47.2M -40.91M -38.35M -34.97M -65.8M -4.5B -66.85M -452M -176M -2.25B -177M -173M -7.52B -222M -192M -180M -164M -309M -21.15B -314M -2.12B -828M -10.59B -832M -814M -35.31B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
13/08/26 US$0.5600 +0.04% 163,720
12/08/26 US$0.5598 +0.46% 181,804
11/08/26 US$0.5573 -3.09% 163,690
10/08/26 US$0.5750 +4.45% 721,899
07/08/26 US$0.5505 -3.42% 201,629
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5600USD
Average target price
3.333USD
Spread / Average Target
+495.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock